2
|
Durcan L, Clarke WA, Magder LS, Petri M. Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence. J Rheumatol 2015; 42:2092-7. [PMID: 26428205 DOI: 10.3899/jrheum.150379] [Citation(s) in RCA: 135] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/22/2015] [Indexed: 01/15/2023]
Abstract
OBJECTIVE Hydroxychloroquine (HCQ) is used for its effect on systemic lupus erythematosus (SLE) disease activity and longterm benefits. This can be limited by adherence. One way to assess adherence is to measure blood levels. Conflicting data exist regarding blood levels and disease activity. There is disagreement about dosing; rheumatologists recommend weight-based dosing while some other specialists advocate height-based "ideal body weight" dosing. METHODS Patients were prescribed HCQ not exceeding 6.5 mg/kg (max 400 mg/day). In hemodialysis, the dose was 200 mg after each session, and in renal insufficiency it was 200 mg/day. Levels were measured at each visit with a therapeutic range of 500-2000 ng/ml. Patients were divided according to baseline blood level. To assess the effect of measurement and counseling on adherence, we compared the proportion of patients with a level of 500 ng/ml or higher based on the number of prior assessments. RESULTS The proportion of patients with HCQ levels in the therapeutic range differed significantly by age, sex, and Vitamin D level. There was a trend toward lower levels with renal failure. Blood levels were similar regardless of height and ideal body weight. Comparing those with undetectable, subtherapeutic, and therapeutic levels, disease activity decreased (SLE Disease Activity Index 2.92, 2.36, and 2.20, p = 0.04 for trend). At first, 56% were therapeutic, and by the third measurement this increased to 80% (p ≤ 0.0001). CONCLUSION There was a trend toward higher disease activity with lower HCQ levels. Renal failure dosing led to suboptimum levels. We show that weight-based dosing (max 400 mg daily) is appropriate and that height does not appear to influence levels. Measurement, counseling, and repeated testing can increase adherence rates.
Collapse
Affiliation(s)
- Laura Durcan
- From the Department of Rheumatology, Johns Hopkins University School of Medicine; Department of Pathology, Clinical Chemistry, Johns Hopkins University Hospital, Baltimore; Department of Epidemiology and Public Health, University of Maryland, College Park, Maryland, USA.L. Durcan, MD, Department of Rheumatology, Johns Hopkins University School of Medicine; W.A. Clarke, PhD, Department of Pathology, Clinical Chemistry, Johns Hopkins University Hospital; L.S. Magder, MPH, PhD, Department of Epidemiology and Public Health, University of Maryland; M. Petri, MD, MPH, Department of Rheumatology, Johns Hopkins University School of Medicine
| | - William A Clarke
- From the Department of Rheumatology, Johns Hopkins University School of Medicine; Department of Pathology, Clinical Chemistry, Johns Hopkins University Hospital, Baltimore; Department of Epidemiology and Public Health, University of Maryland, College Park, Maryland, USA.L. Durcan, MD, Department of Rheumatology, Johns Hopkins University School of Medicine; W.A. Clarke, PhD, Department of Pathology, Clinical Chemistry, Johns Hopkins University Hospital; L.S. Magder, MPH, PhD, Department of Epidemiology and Public Health, University of Maryland; M. Petri, MD, MPH, Department of Rheumatology, Johns Hopkins University School of Medicine
| | - Laurence S Magder
- From the Department of Rheumatology, Johns Hopkins University School of Medicine; Department of Pathology, Clinical Chemistry, Johns Hopkins University Hospital, Baltimore; Department of Epidemiology and Public Health, University of Maryland, College Park, Maryland, USA.L. Durcan, MD, Department of Rheumatology, Johns Hopkins University School of Medicine; W.A. Clarke, PhD, Department of Pathology, Clinical Chemistry, Johns Hopkins University Hospital; L.S. Magder, MPH, PhD, Department of Epidemiology and Public Health, University of Maryland; M. Petri, MD, MPH, Department of Rheumatology, Johns Hopkins University School of Medicine
| | - Michelle Petri
- From the Department of Rheumatology, Johns Hopkins University School of Medicine; Department of Pathology, Clinical Chemistry, Johns Hopkins University Hospital, Baltimore; Department of Epidemiology and Public Health, University of Maryland, College Park, Maryland, USA.L. Durcan, MD, Department of Rheumatology, Johns Hopkins University School of Medicine; W.A. Clarke, PhD, Department of Pathology, Clinical Chemistry, Johns Hopkins University Hospital; L.S. Magder, MPH, PhD, Department of Epidemiology and Public Health, University of Maryland; M. Petri, MD, MPH, Department of Rheumatology, Johns Hopkins University School of Medicine
| |
Collapse
|
3
|
Angelakis E, Million M, Kankoe S, Lagier JC, Armougom F, Giorgi R, Raoult D. Abnormal weight gain and gut microbiota modifications are side effects of long-term doxycycline and hydroxychloroquine treatment. Antimicrob Agents Chemother 2014; 58:3342-7. [PMID: 24687497 PMCID: PMC4068504 DOI: 10.1128/aac.02437-14] [Citation(s) in RCA: 77] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2014] [Accepted: 03/24/2014] [Indexed: 12/14/2022] Open
Abstract
Doxycycline has been proposed for the treatment of malnourished children in developing countries, and its use has been associated with weight gain in healthy volunteers. No previous studies have assessed abnormal weight gain as a putative side effect of long-term doxycycline treatment; thus, the objective of the present study was to characterize this phenomenon. We also analyzed the role of the gut microbiota in this effect. We assessed changes in the body mass index in Q fever endocarditis patients treated with doxycycline and hydroxychloroquine and healthy individuals with no antibiotic treatment. Abnormal weight gain was defined as a gain in weight above that of the controls. The fecal samples were examined using molecular assays for Methanobrevibacter smithii, Bacteroidetes, Firmicutes, Escherichia coli, Lactobacillus, Lactobacillus reuteri, and total bacterial concentrations. We examined 82 patients, including 48 patients with Q fever endocarditis and 34 controls. Approximately 23% of the treated patients showed abnormal weight gain (P = 0.001). Patients treated with doxycycline and hydroxychloroquine presented significantly lower concentrations of Bacteroidetes (P = 0.002), Firmicutes (P = 0.01), and Lactobacillus (P = 0.02). The linear regression analysis revealed that the duration of treatment was significantly associated with a decrease in Bacteroidetes (P = 0.0001), Firmicutes (P = 0.002), and total bacteria (P < 0.00001). Abnormal weight gain is a side effect of long-term doxycycline and hydroxychloroquine treatment. Gut microbiota modifications at the phylum level could play an instrumental role in this effect. We highlight the need for specific nutritional care in patients undergoing long-term antibiotic treatment, particularly treatment involving the use of doxycycline.
Collapse
Affiliation(s)
- Emmanouil Angelakis
- Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes, Faculté de Médecine et de Pharmacie, CNRS UMR 7278, IRD 198, Aix-Marseille Université, Marseille, France
| | - Matthieu Million
- Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes, Faculté de Médecine et de Pharmacie, CNRS UMR 7278, IRD 198, Aix-Marseille Université, Marseille, France
| | - Sallah Kankoe
- UMR 912 SESSTIM, INSERM/IRD/Aix-Marseille Université, Faculté de Médecine, Marseille Cedex, France
| | - Jean-Christophe Lagier
- Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes, Faculté de Médecine et de Pharmacie, CNRS UMR 7278, IRD 198, Aix-Marseille Université, Marseille, France
| | - Fabrice Armougom
- Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes, Faculté de Médecine et de Pharmacie, CNRS UMR 7278, IRD 198, Aix-Marseille Université, Marseille, France
| | - Roch Giorgi
- UMR 912 SESSTIM, INSERM/IRD/Aix-Marseille Université, Faculté de Médecine, Marseille Cedex, France
| | - Didier Raoult
- Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes, Faculté de Médecine et de Pharmacie, CNRS UMR 7278, IRD 198, Aix-Marseille Université, Marseille, France
| |
Collapse
|
4
|
Abstract
Osteoarticular infection is an uncommon presentation of Q fever. Positron emission tomography (PET) scanning is a valuable tool for the diagnosis of Coxiella burnetii graft prosthesis infection and endocarditis. Our objective was to test a series of culture-negative osteoarticular samples using molecular assays for Coxiella burnetii. We tested for C. burnetii by molecular assays targeting the IS1111 and the IS30A spacer regions, using culture-negative osteoarticular samples obtained in our laboratory between January 2011 and December 2012. We examine a total of 1,410 osteoarticular samples, and we observed two cases of arthritis and subacromial bursitis caused by C. burnetii. The infections were localized using PET scanning, and the diagnosis was confirmed through serology. For one, a C. burnetii strain with a multispacer sequence type 8 genotype was isolated from synovial fluid culture. Q fever articular infections could be undiagnosed because of the long evolution of articular attack, and patients with high antibody titers against C. burnetii should be tested using PET scanning to localize the site of infection.
Collapse
|